| Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system B Sarkadi, L Homolya, G Szakács, A Váradi Physiological reviews 86 (4), 1179-1236, 2006 | 948 | 2006 |
| An inventory of the human ABC proteins I Klein, B Sarkadi, A Váradi Biochimica et Biophysica Acta (BBA)-Biomembranes 1461 (2), 237-262, 1999 | 827 | 1999 |
| The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox) G Szakács, A Váradi, C Özvegy-Laczka, B Sarkadi Drug discovery today 13 (9-10), 379-393, 2008 | 733 | 2008 |
| Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells C Özvegy, T Litman, G Szakács, Z Nagy, S Bates, A Váradi, B Sarkadi Biochemical and biophysical research communications 285 (1), 111-117, 2001 | 436 | 2001 |
| Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain E Bakos, R Evers, G Szakács, GE Tusnády, E Welker, K Szabó, ... Journal of Biological Chemistry 273 (48), 32167-32175, 1998 | 420 | 1998 |
| High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter C Özvegy-Laczka, T Hegedűs, G Várady, O Ujhelly, JD Schuetz, A Varadi, ... Molecular pharmacology 65 (6), 1485-1495, 2004 | 415 | 2004 |
| Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions É Bakos, R Evers, E Sinkó, A Váradi, P Borst, B Sarkadi Molecular pharmacology 57 (4), 760-768, 2000 | 402 | 2000 |
| ABCG2–a transporter for all seasons B Sarkadi, C Özvegy-Laczka, K Német, A Váradi FEBS letters 567 (1), 116-120, 2004 | 380 | 2004 |
| MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping AJ Smith, A van Helvoort, G van Meer, K Szabó, E Welker, G Szakács, ... Journal of Biological Chemistry 275 (31), 23530-23539, 2000 | 362 | 2000 |
| Membrane topology distinguishes a subfamily of the ATP-binding cassette (ABC) transporters GE Tusnády, É Bakos, A Váradi, B Sarkadi FEBS letters 402 (1), 1-3, 1997 | 318 | 1997 |
| Common evolutionary origin of the fibrin‐binding structures of fibronectin and tissue‐type plasminogen activator L Bányai, A Váradi, L Patthy FEBS letters 163 (1), 37-41, 1983 | 315 | 1983 |
| Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate A Váradi, B Sarkadi Biofactors 17 (1-4), 103-114, 2003 | 298 | 2003 |
| ABCC6–mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation—brief report RS Jansen, S Duijst, S Mahakena, D Sommer, F Szeri, A Váradi, A Plomp, ... Arteriosclerosis, thrombosis, and vascular biology 34 (9), 1985-1989, 2014 | 297 | 2014 |
| The role of multidrug transporters in drug availability, metabolism and toxicity A Bodó, É Bakos, F Szeri, A Váradi, B Sarkadi Toxicology letters 140, 133-143, 2003 | 295 | 2003 |
| Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6) A Iliás, Z Urbán, TL Seidl, O Le Saux, E Sinkó, CD Boyd, B Sarkadi, ... Journal of Biological Chemistry 277 (19), 16860-16867, 2002 | 295 | 2002 |
| Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter: modulation of substrate specificity by a point mutation C Ozvegy, A Váradi, B Sarkadi Journal of Biological Chemistry 277 (50), 47980-47990, 2002 | 293 | 2002 |
| Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib) NB Elkind, Z Szentpétery, Á Apáti, C Ozvegy-Laczka, G Várady, O Ujhelly, ... Cancer research 65 (5), 1770-1777, 2005 | 285 | 2005 |
| Membrane Topology and Glycosylation of the Human Multidrug Resistance-associated Protein (∗) E Bakos, T Hegedüs, Z Holló, E Welker, GE Tusnády, GJR Zaman, ... Journal of Biological Chemistry 271 (21), 12322-12326, 1996 | 276 | 1996 |
| Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties C Hegedűs, C Özvegy‐Laczka, A Apati, M Magocsi, K Nemet, L Őrfi, ... British journal of pharmacology 158 (4), 1153-1164, 2009 | 257 | 2009 |
| Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1 T Hegedűs, L Őrfi, A Seprődi, A Váradi, B Sarkadi, G Kéri Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1587 (2-3 …, 2002 | 254 | 2002 |
